Atia R, Jouve L, Knoeri J, Georgeon C, Laroche L, Borderie V, Bouheraoua N
Service d'ophtalmologie 5, centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
Service d'ophtalmologie 5, centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France; Inserm UMR S 968, université Pierre-et-Marie-Curie-Paris-VI, institut de la vision, 75012 Paris, France.
J Fr Ophtalmol. 2018 Jun;41(6):560-568. doi: 10.1016/j.jfo.2017.12.007. Epub 2018 Jun 11.
Infectious keratitis are a frequent cause of ocular morbidity. Today, new treatments are necessary to combat the emergence of antibiotic resistant germs. Corneal collagen cross-linking has been suggested to treat corneal infectious (PACK-CXL). Its action would be both antimicrobial and protective for the cornea, increasing its biochemical resistence to proteolytic enzymes. In vivo, PACK-CXL might demonstrate good efficacy against bacterial keratitis, contrary to herpetic keratitis for which it is contraindicated. For fungal or amoebic keratitis, results are uncertain regarding its safety and efficacy. The purpose of this paper is to clarify the use of corneal collagen cross-linking to treat infectious keratitis.
感染性角膜炎是导致眼部发病的常见原因。如今，需要新的治疗方法来应对抗生素耐药菌的出现。有人提出用角膜胶原交联术来治疗角膜感染（PACK-CXL）。其作用兼具抗菌性和对角膜的保护性，可增强角膜对蛋白水解酶的生化抵抗力。在体内，PACK-CXL对细菌性角膜炎可能显示出良好疗效，而对疱疹性角膜炎则禁用。对于真菌性或阿米巴性角膜炎，其安全性和疗效尚不确定。本文旨在阐明角膜胶原交联术在治疗感染性角膜炎中的应用。
